Siemens Healthineers and Mayo Clinic Add Six Clinical Programs in Brain, Prostate, and Liver Disease

Medical imaging and clinical practice often advance on separate timelines. Hardware and AI capabilities develop in engineering labs; whether those capabilities translate into better patient care depends on whether someone builds the clinical programs to test and implement them. Siemens Healthineers and Mayo Clinic have formalized an agreement to do exactly that across six disease areas, signing a new collaboration covering neurodegenerative conditions, prostate cancer, and metastatic liver tumors.

The partnership adds to an existing relationship between the two organizations, extending it into some of medicine's more technically demanding diagnostic and treatment challenges. Each of the six programs targets a specific gap between what imaging and AI can now demonstrate in research settings and what patients currently receive in clinical care.

Neurodegenerative Disease: Better Data at Every Stage

Conditions like Alzheimer's disease and Parkinson's disease are notoriously difficult to track with conventional MRI. The collaboration will develop AI-enabled MRI protocols aimed at improving diagnostic accuracy and enabling more precise monitoring of disease progression over time. Current imaging often provides insufficient resolution to detect subtle structural changes relevant to early-stage neurological disease or to assess whether a treatment is slowing progression.

A related program establishes an ultra-high-field MRI innovation center at Mayo. Systems operating above the standard 1.5 or 3 Tesla field strength found in most clinical environments offer substantially higher resolution and enhanced tissue contrast. The collaboration will apply this capability specifically to diagnostic and surgical planning for patients with complex neurological disease, where detailed anatomical information can be the difference between safe and unsafe intervention.

Prostate Cancer: Reducing Unnecessary Biopsies

Current diagnostic pathways for prostate cancer often involve multiple biopsies, each carrying risks of infection, bleeding, and patient discomfort. The collaboration will investigate whether AI-assisted imaging can reliably identify cases that do not require biopsy - sparing patients the procedure without compromising diagnostic accuracy. The program will also examine how advanced imaging can be more tightly integrated into both diagnosis and treatment planning, with the aim of reducing unnecessary interventions while improving care for cases that need attention.

Liver Metastases: Minimally Invasive Treatment Suites

For cancer that has spread to the liver, the collaboration focuses on the physical environment where treatment occurs. The program will develop minimally invasive, image-guided interventional suites - specialized facilities equipped with advanced imaging technology for precise detection and treatment of liver tumors. These environments enable procedures that would otherwise require open surgery, reducing recovery time and associated risk.

Digital Twin Surgery Planning

Digital twin technologies create virtual replicas of patients or clinical processes, allowing surgeons to simulate interventions before performing them. The collaboration will develop this capability for surgical care applications - improving pre-operative preparation, reducing complication rates, and potentially optimizing operating room workflows. By modeling a specific patient's anatomy virtually before a procedure, surgeons can identify and plan around individual anatomical variations that might otherwise become intraoperative surprises.

Theranostics: Imaging and Treatment from the Same Target

The sixth program establishes a whole-body PET/CT and PET/MR innovation center emphasizing theranostics - an approach that uses the same molecular target for both imaging a disease and delivering treatment to it. The combination of simultaneous anatomical MR imaging and metabolic PET data provides the multi-dimensional information increasingly required for personalized cancer treatment planning. By seeing exactly where a therapy will act before delivering it, clinicians can refine dosing, timing, and targeting in ways that conventional approaches do not permit.

What Collaboration Actually Delivers

Eric Williamson, professor and chair of diagnostic radiology at Mayo Clinic, described the program's patient-facing goals: making care more precise, less invasive, and more responsive to each patient's individual needs. John Kowal, president and head of the Americas at Siemens Healthineers, framed the organizational rationale: the company's purpose centers on improving diagnosis and treatment of neurodegenerative disease and cancer, and Mayo's clinical volume and expertise provides the environment where new technologies can be rigorously tested.

The agreement creates conditions for clinical translation. Whether and how quickly any of these technologies moves into widespread practice will depend on clinical validation results, regulatory review, and the practical realities of integrating new systems into busy environments. The six programs are the beginning of that process, not the end.